Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The American Academy of Neurology and the National Multiple Sclerosis Society are awarding the 2013 John Dystel Prize for MS Research to George C. Ebers, MD, a leading researcher with the University of Oxford and Oxford University Hospitals Trust in Oxford, United Kingdom.

The American Academy of Neurology and the National Multiple Sclerosis Society are awarding the 2013 John Dystel Prize for MS Research to George C. Ebers, MD, a leading researcher with the University of Oxford and Oxford University Hospitals Trust in Oxford, United Kingdom. Ebers will receive the award at the Academy’s 65th Annual Meeting in San Diego, March 16-23, 2013. The Annual Meeting is the world’s largest gathering of neurologists with more than 10,000 attendees and more than 2,300 scientific presentations on the latest research advancements in brain disease.

The John Dystel Prize recognizes a significant contribution to research in the understanding, treatment or prevention of multiple sclerosis (MS).

Ebers’ research has focused on genetic and environmental influences on MS risks.

“We have found that MS risk factors previously considered to be genetic can be changed based on environment, strongly implicating gene-environment interaction. Our studies highlight how climate and diet relate to factors leading to MS, which can be views as a largely preventable disease. Vitamin D exposure appears to be the main factor determining geographical risk” said Ebers. This award is made possible through a special contribution from the John Dystel Multiple Sclerosis Research Fund at the National Multiple Sclerosis Society. “John Dystel was an MS patient I saw while I was working in New York, so it is very gratifying to receive this award in his honor,” said Ebers. 

The American Academy of Neurology, an association of more than 25,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer’s disease, epilepsy, Parkinson’s disease and multiple sclerosis. 

Source: American Academy of Neurology

Links: 
Learn more about multiple sclerosis at http://www.aan.com/patients
Dr. George Ebers

Similar stories

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.

MRC HIU appoints new Director

Awards and Appointments General

We are pleased to announce that Professor Alison Simmons has been appointed as the new Director of the MRC Human Immunology Unit.

New Year's Honours 2021

Awards and Appointments General

Members of the Medical Sciences Division have been recognised in the New Year's Honours list for 2021.

Oxford University awarded £2.4 million to fund DPhil research in inflammation, immunology and musculoskeletal disease

Awards and Appointments General

Oxford University has been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.

Professor Sir Rory Collins awarded the MRC Millennium Medal 2020

Awards and Appointments General

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Awards and Appointments General Innovation

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.